Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

discontinuation rates for disturbance in attention that were at least three times greater than what was observed in our studies. These results were consistent with the expected profile and previous experience of Qnexa in our studies," stated Leland Wilson, president and chief executive officer of VIVUS. "We believe this additional data further substantiates the safety profile of Qnexa. Taken in the context of the statistically significant weight loss and improvement on co-morbidities, Qnexa has a positive benefit/risk profile. Completion rates for patients on Qnexa were significantly better as compared to placebo in the phase 3 trials. We believe the overall efficacy and safety profile of Qnexa supports approvability."

The company anticipates filing the NDA for Qnexa by the end of 2009.

Previously reported highlights from the EQUIP and CONQUER studies were included in the presentation:

  • Average weight loss of 14.7% (37 lbs) was achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
  • Significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
  • FDA efficacy benchmarks for weight loss agents were exceeded at all three doses of Qnexa tested in the clinical program; and
  • Completion rates up to 69% were significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability.
  • Across both 56-week studies, the most commonly reported side effects were dry mouth, tingling, constipation, altered taste and insomnia.
  • There were no serious adverse events reported for cognitive disorders.

EQUIP (OB-302) Study Overview

The EQUIP study included 1,267 morbidly obese patients (1,050 females and 217 males) across 93 centers in the United States. The average baseline BMI of the study population was 42.1 kg/m(2) and baseline weight was 256 pounds. Patients had
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... Drug Transfer Systems to 2020" report to their ... hazardous to humans has been receiving increasing amounts of ... substances become more clearly understood. For caregivers and their ... of attempts to mitigate exposure to cytotoxic drugs is ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 17, 2011 Attorneys representing a group of U.S. citizens ... the drug thalidomide have filed a lawsuit in federal court ... show the drug was widely distributed in the United States. ... to respond to a number of Freedom of Information Act ...
... WASHINGTON, Nov. 17, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... employers, unions, and state employee plans, according to new ... Care Management Association (PCMA).   The use of these ...
Cached Medicine Technology:Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 2Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 3Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $617 Million in Wisconsin 2
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... Bard, Inc. continue to move forward in the federal ... District of West Virginia, Bernstein Liebhard LLP reports. According ... a Final Order on September 10th that provides for ... Order notes that none of the affected plaintiffs has ...
(Date:9/15/2014)... large cohort analysis from the prospective Prostate, Lung, Colorectal ... who had moderate baldness affecting both the front and ... at a 40% increased risk of developing aggressive prostate ... poorer prognosis relative to non-aggressive prostate cancer) later in ... no significant link between other patterns of baldness and ...
(Date:9/15/2014)... The White House has recently begun shifting ... jail and prison and toward helping them access addiction ... positive change. , The nation is currently grappling with ... to an article from The Washington Post , ... away from using the criminal justice system to address ...
(Date:9/15/2014)... By Maureen Salamon ... (HealthDay News) -- Pediatricians prescribe antibiotics about twice as ... and throat infections, a new study indicates. More ... children and teens may be unnecessary, according to researchers ... excess antibiotic use not only fails to eradicate children,s ...
(Date:9/15/2014)... shown that certain brain regions are associated with ... decision-making. , How and where these specific abilities ... cognition is still under investigation. However, researchers at ... St. Louis, Missouri, believe that several hub regions ... function as an integrated network. , In research ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2Health News:White House Shifts Policy on Drugs 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Network measures predict neuropsychological outcome after brain injury 2
... its new patient-education website, www.CLIclinicalstudy.com , is now “live”. ... enrolling in the Company’s clinical trial and their referring physicians ... underlies it, and the location of the study’s sites. ... ...
... help consumers get,accurate, dependable information about healthcare ... support consumer,engagement and improved quality in healthcare, ... consumer-focused, internet-based public,reporting. These guidelines will assist ... in an evidence-based and,consumer-friendly format that can ...
... (October 26, 2008) A single administration of a novel, ... that were more than 20 times higher than those ... according to a study by NanoBio Corporation. The new ... produce this effect. , Results of the study are ...
... blood that was 29 days or older faced twice the ... who receive a transfusion of stored blood that is 29 ... or more serious infections compared to those who get "fresher" ... that current U.S. regulations set the upper limit for blood ...
... of candy, ST. LOUIS, Oct. 28 The ... year, and a sizeable portion of that indulgence,is eaten ... will,simply create an expanded beltline. However, for the more ... can pose more,tricky consequences., To help ease candy ...
... Resources to Prevent Millions in Lost Wages, SAN ... of the flu are reported annually, financially challenging working,families ... days. QuickHealth meets,the challenge by providing updated information and ... to clarify treatment options and to help,them make better ...
Cached Medicine News:Health News: Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb Ischemia 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 3Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 5Health News:New intranasal influenza vaccine triggers robust immunity with significantly less antigen 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 2Health News:Orthodontists Offer Sweet Incentives for Tricky Halloween Treats 3Health News:75 Million Missed Work Days Expected This Flu Season 2Health News:75 Million Missed Work Days Expected This Flu Season 3
... an ultra-capacity bacterial growth system, combines ... a high-capacity format for bacterial growth. ... with Bioneer's HT-Prep™ Automatic DNA Extractor. ... advantages over traditional floor shakers. Plate-holding ...
Inquire...
... Refrigerated incubators,Two refrigerated incubators ... life and life cycle,testing. Microprocessor ... digital temperature display. High/low audible ... contacts. Additional internal chamber safety ...
Inquire...
Medicine Products: